October 26, 2010
Law360
Abbott Laboratories and the Wisconsin Alumni Research Foundation (WARF) have slapped Anchen Pharmaceuticals Inc. with a patent infringement suit over the generic-drug maker's efforts to introduce its own version of kidney disease drug Zemplar®. The suit comes after Anchen filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration seeking approval to market a generic version of Zemplar® in 1 mcg, 2 mcg and 4 mcg capsules before the patent-in-suit, issued to WARF in 1996 and titled “19-nor-Vitamin D compounds”, expires in December 2013. Abbott and WARF are seeking judgments that the patent-in-suit is valid and enforceable and that Anchen will infringe the patent by offering to sell a generic version of Zemplar® before the patent expires. Abbott and WARF are represented by Finnegan.
Announcement
September 3, 2024
Award/Ranking
Savoy Magazine Names Mareesa Frederick on its 2024 Most Influential Lawyers List
August 2, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.